Komaki R, Cox J D, Stark R
Int J Radiat Oncol Biol Phys. 1983 Oct;9(10):1467-70. doi: 10.1016/0360-3016(83)90319-x.
From January 1970 through December 1981, 469 patients with histologically or cytologically proven adenocarcinoma (AC) (349) and large cell carcinoma (LC) (120) of the lung were seen at the Department of Radiation Oncology, Medical College of Wisconsin Affiliated Hospitals. One quarter (126/469) of these patients had brain metastasis: 48 patients presented with brain metastasis (AC 35/349 = 10% and LC 13/120 = 11%) and 78 patients subsequently developed brain metastasis (AC 61/314 = 19%, LC 17/107 = 16%). Those patients who received prophylactic cranial irradiation were excluded from this study. Brain was the dominant site of metastasis in 82 patients who received only cranial + thoracic irradiation; 37 patients (17 simultaneous, 20 metachronous) also required irradiation of other sites of metastasis. All 17 patients with LC, and 47/61 (77%) with AC who developed metachronous brain metastasis did so within one year. The cumulative probability of brain metastasis increased with survival to the levels predicted by autopsy studies. Therapeutic brain irradiation may result in long-term survival in patients with single organ brain metastasis. Three of 119 patients who underwent whole brain irradiation for metastasis, are alive at 60 (LC), 48 (AC) and 48 months (AC) after treatment. Since patients with AC and LC so frequently develop brain metastasis and the brain may be the only site of metastasis, prophylactic cranial irradiation may significantly reduce morbidity and mortality from these diseases.
1970年1月至1981年12月期间,威斯康星医学院附属医院放射肿瘤学系收治了469例经组织学或细胞学证实为肺腺癌(AC)(349例)和大细胞癌(LC)(120例)的患者。这些患者中有四分之一(126/469)发生了脑转移:48例患者初诊时即有脑转移(AC 35/349 = 10%,LC 13/120 = 11%),78例患者随后发生脑转移(AC 61/314 = 19%,LC 17/107 = 16%)。接受过预防性颅脑照射的患者被排除在本研究之外。在仅接受颅脑+胸部照射的82例患者中,脑是主要的转移部位;37例患者(17例同时性转移,20例异时性转移)还需要对其他转移部位进行照射。所有17例LC患者以及发生异时性脑转移的AC患者中的47/61(77%)均在1年内发生了脑转移。脑转移的累积概率随着生存率的提高而增加,达到尸检研究预测的水平。对单器官脑转移患者进行治疗性颅脑照射可能会带来长期生存。119例因转移接受全脑照射的患者中有3例在治疗后60个月(LC)、48个月(AC)和48个月(AC)时仍存活。由于AC和LC患者经常发生脑转移,且脑可能是唯一的转移部位,预防性颅脑照射可能会显著降低这些疾病的发病率和死亡率。